Response to ‘Clinical Efficacy of Tofacitinib in Moderate to Severe Ulcerative Colitis’

We would like to thank Dr Ng for the interest and comments regarding our study ‘Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience’.1 The comments pertain to the plausibility of stable haemoglobin [Hb] levels in the context of moderately to severely active disease, which did not increase with therapy, and the significance of tofacitinib-induced hyperlipidaemia in our study cohort....